Tracing the protectors path from the germ line to the genome

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 35, 2010, Pages 15318-15325

  Coutandin, Daniel ^a   Der Ou, Horng ^a,b   Löhr, Frank ^a   Dötsch, Volker ^a  

^a GOETHE UNIVERSITY   (Germany)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

Evolution; Oligomerization; p53; p63; p73

Indexed keywords

PROTEIN; PROTEIN P53; PROTEIN P63; PROTEIN P73;

CAENORHABDITIS ELEGANS; CARBOXY TERMINAL SEQUENCE; EVOLUTION; GENE; GENE DUPLICATION; GENOME; GERM CELL; GERM LINE; NONHUMAN; OLIGOMERIZATION; ORTHOLOGY; PARALOGY; PHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; QUALITY CIRCLE; REVIEW; RNA SPLICING; SOMATIC MUTATION; TISSUE DISTRIBUTION; TUMOR SUPPRESSOR GENE;

ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; DNA; DNA-BINDING PROTEINS; EVOLUTION, MOLECULAR; GENOME; GERM CELLS; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; SEQUENCE HOMOLOGY, AMINO ACID; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

CAENORHABDITIS ELEGANS; HOMO SAPIENS; INVERTEBRATA; MAMMALIA;

EID: 77957273236     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1001069107     Document Type: Review

References (133)

1. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
2. Yang A, Kaghad M, Caput D, McKeon F (2002) On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet 18:90-95. (Pubitemid 34127808)
3. Levine AJ, Oren M (2009) The first 30 years of p53: Growing ever more complex. Nat Rev Cancer 9:749-758.
4. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253: 49-53.
5. Kaghad M, et al. (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809-819.
6. Yang A, et al. (1998) p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2:305-316.
7. Schmale H, Bamberger C (1997) A novel protein with strong homology to the tumor suppressor p53. Oncogene 15:1363-1367. (Pubitemid 27429753)
8. Senoo M, et al. (1998) A second p53-related protein, p73L, with high homology to p73. Biochem Biophys Res Commun 248:603-607.
9. Trink B, et al. (1998) A new human p53 homologue. Nat Med 4:747-748.
10. Flores ER, et al. (2002) p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416:560-564.
11. Gong JG, et al. (1999) The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399:806-809.
12. Rossi M, Sayan AE, Terrinoni A, Melino G, Knight RA (2004) Mechanism of induction of apoptosis by p73 and its relevance to neuroblastoma biology. Ann N Y Acad Sci 1028:143-149. (Pubitemid 40361818)
13. Kovalev S, Marchenko N, Swendeman S, LaQuaglia M, Moll UM (1998) Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines. Cell Growth Differ 9:897-903.
14. Ichimiya S, et al. (2001) Genetic analysis of p73 localized at chromosome 1p36.3 in primary neuroblastomas. Med Pediatr Oncol 36:42-44.
15. Ichimiya S, et al. (1999) p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent. Oncogene 18:1061-1066.
16. Collavin L, Lunardi A, Del Sal G (2010) p53-family proteins and their regulators: Hubs and spokes in tumor suppression. Cell Death Differ 17:901-911.
17. Wade M, Wang YV, Wahl GM (2010) The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 20:299-309.
18. Pietsch EC, Sykes SM, McMahon SB, Murphy ME (2008) The p53 family and programmed cell death. Oncogene 27:6507-6521.
19. Deyoung MP, Ellisen LW (2007) p63 and p73 in human cancer: Defining the network. Oncogene 26:5169-5183.
20. Vilgelm A, El-Rifai W, Zaika A (2008) Therapeutic prospects for p73 and p63: Rising from the shadow of p53. Drug Resist Updat 11:152-163.
21. Vousden KH, Prives C (2009) Blinded by the light: The growing complexity of p53. Cell 137:413-431.
22. Vousden KH, Lane DP (2007) p53 in health and disease. Nat Rev Mol Cell Biol 8:275-283.
23. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP (2009) Awakening guardian angels: Drugging the p53 pathway. Nat Rev Cancer 9:862-873.
24. McKeon F, Melino G (2007) Fog of war: The emerging p53 family. Cell Cycle 6:229-232. (Pubitemid 46271566)
25. Riley T, Sontag E, Chen P, Levine A (2008) Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9:402-412.
26. Hupp TR, Lane DP (1994) Allosteric activation of latent p53 tetramers. Curr Biol 4:865-875. (Pubitemid 124001236)
27. Jayaraman J, Prives C (1995) Activation of p53 sequence specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 81:1021-1029.
28. Ayed A, et al. (2001) Latent and active p53 are identical in conformation. Nat Struct Biol 8:756-760.
29. De Laurenzi V, et al. (1998) Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med 188:1763-1768.
30. De Laurenzi VD, et al. (1999) Additional complexity in p73: Induction by mitogens in lymphoid cells and identification of two new splicing variants epsilon and zeta. Cell Death Differ 6:389-390.
31. Chi SW, Ayed A, Arrowsmith CH (1999) Solution structure of a conserved C-terminal domain of p73 with structural homology to the SAM domain. EMBO J 18:4438-4445.
32. Takada N, Ozaki T, Ichimiya S, Todo S, Nakagawara A (1999) Identification of a transactivation activity in the COOH-terminal region of p73 which is impaired in the naturally occurring mutants found in human neuroblastomas. Cancer Res 59:2810-2814. (Pubitemid 29283114)
33. Ozaki T, et al. (1999) Deletion of the COOH-terminal region of p73alpha enhances both its transactivation function and DNA-binding activity but inhibits induction of apoptosis in mammalian cells. Cancer Res 59:5902-5907.
34. Serber Z, et al. (2002) A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism. Mol Cell Biol 22:8601-8611.
35. Straub WE, et al. (2010) The C-terminus of p63 contains multiple regulatory elements with different functions. Cell Death Dis 1:e5.
36. Fujita K, et al. (2009) p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol 11:1135-1142.
37. Chen J, et al. (2009) p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. Genes Dev 23:278-290.
38. Bourdon JC, et al. (2005) p53 isoforms can regulate p53 transcriptional activity. Genes Dev 19:2122-2137.
39. Courtois S, de Fromentel CC, Hainaut P (2004) p53 protein variants: Structural and functional similarities with p63 and p73 isoforms. Oncogene 23:631-638.
40. Lane DP, et al. (2010) Mdm2 and p53 are highly conserved from placozoans to man. Cell Cycle 9: 540-547.
41. Lane DP, et al. (2010) The Mdm2 and p53 genes are conserved in the Arachnids. Cell Cycle 9:748-754.
42. Pankow S, Bamberger C (2007) The p53 tumor suppressor-like protein nvp63 mediates selective germ cell death in the sea anemone Nematostella vectensis. PLoS ONE 2:e782. (Pubitemid 351425692)
43. Derry WB, Putzke AP, Rothman JH (2001) Caenorhabditis elegans p53: Role in apoptosis, meiosis, and stress resistance. Science 294:591-595.
44. Ollmann M, et al. (2000) Drosophila p53 is a structural and functional homolog of the tumor suppressor p53. Cell 101:91-101.
45. Brodsky MH, et al. (2000) Drosophila p53 binds a damage response element at the reaper locus. Cell 101:103-113.
46. Donehower LA, et al. (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221.
47. Donehower LA, Lozano G (2009) 20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer 9:831-841.
48. Yang A, et al. (1999) p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398:714-718.
49. Yang A, et al. (2000) p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404:99-103.
50. Mills AA, et al. (1999) p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398:708-713.
51. Rosenbluth JM, Pietenpol JA (2008) The jury is in: p73 is a tumor suppressor after all. Genes Dev 22: 2591-2595.
52. Moll UM, Slade N (2004) p63 and p73: Roles in development and tumor formation. Mol Cancer Res 2:371-386. (Pubitemid 39031071)
53. Celli J, et al. (1999) Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell 99:143-153.
54. McGrath JA, et al. (2001) Hay-Wells syndrome is caused by heterozygous missense mutations in the SAM domain of p63. Hum Mol Genet 10:221-229.
55. Rinne T, Bolat E, Meijer R, Scheffer H, van Bokhoven H (2009) Spectrum of p63 mutations in a selected patient cohort affected with ankyloblepharon- ectodermal defects-cleft lip/palate syndrome (AEC). Am J Med Genet A 149A:1948-1951.
56. Barrow LL, et al. (2002) Analysis of the p63 gene in classical EEC syndrome, related syndromes, and non-syndromic orofacial clefts. J Med Genet 39:559-566.
57. Senoo M, Pinto F, Crum CP, McKeon F (2007) p63 is essential for the proliferative potential of stem cells in stratified epithelia. Cell 129:523-536.
58. Koster MI, Kim S, Mills AA, DeMayo FJ, Roop DR (2004) p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev 18: 126-131. (Pubitemid 38141780)
59. Knudson AG, Jr (1971) Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820-823.
60. Venkatachalam S, et al. (1998) Retention of wild-type p53 in tumors from p53 heterozygous mice: Reduction of p53 dosage can promote cancer formation. EMBO J 17:4657-4667.
61. Schumacher B, Hofmann K, Boulton S, Gartner A (2001) The C. elegans homolog of the p53 tumor suppressor is required for DNA damage-induced apoptosis. Curr Biol 11:1722-1727.
62. Schumacher B, et al. (2005) C. elegans ced-13 can promote apoptosis and is induced in response to DNA damage. Cell Death Differ 12:153-161. (Pubitemid 40220646)
63. Tomasini R, et al. (2008) TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev 22:2677-2691.
64. Tomasini R, et al. (2009) TAp73 regulates the spindle assembly checkpoint by modulating BubR1 activity. Proc Natl Acad Sci USA 106:797-802.
65. Suh EK, et al. (2006) p63 protects the female germ line during meiotic arrest. Nature 444:624-628.
66. Flores ER, et al. (2005) Tumor predisposition in mice mutant for p63 and p73: Evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7: 363-373.
67. Nemajerova A, Palacios G, Nowak NJ, Matsui S, Petrenko O (2009) Targeted deletion of p73 in mice reveals its role in T cell development and lymphoma-genesis. PLoS ONE 4:e7784.
68. Perez-Losada J, Wu D, DelRosario R, Balmain A, Mao JH (2005) p63 and p73 do not contribute to p53-mediated lymphoma suppressor activity in vivo. Oncogene 24:5521-5524.
69. Senoo M, Manis JP, Alt FW, McKeon F (2004) p63 and p73 are not required for the development and p53- dependent apoptosis of T cells. Cancer Cell 6:85-89.
70. Keyes WM, et al. (2006) p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors. Proc Natl Acad Sci USA 103: 8435-8440.
71. Guo X, et al. (2009) TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat Cell Biol 11: 1451-1457.
72. Keyes WM, et al. (2005) p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev 19:1986-1999.
73. Hong H, et al. (2009) Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 460:1132-1135.
74. Kawamura T, et al. (2009) Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 460:1140-1144.
75. Marión RM, et al. (2009) A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 460:1149-1153.
76. Li H, et al. (2009) The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 460:1136-1139.
77. Utikal J, et al. (2009) Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 460:1145-1148.
78. Liu Y, et al. (2009) p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell 4:37-48.
79. Meletis K, et al. (2006) p53 suppresses the self-renewal of adult neural stem cells. Development 133:363-369. (Pubitemid 43210724)
80. Lee KH, et al. (2010) A genomewide study identifies the Wnt signaling pathway as a major target of p53 in murine embryonic stem cells. Proc Natl Acad Sci USA 107:69-74.
81. Lin T, et al. (2005) p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol 7:165-171.
82. Cicalese A, et al. (2009) The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 138:1083-1095.
83. Roegiers F, Jan YN (2004) Asymmetric cell division. Curr Opin Cell Biol 16:195-205.
84. Colaluca IN, et al. (2008) NUMB controls p53 tumour suppressor activity. Nature 451:76-80.
85. Hu W, Feng Z, Teresky AK, Levine AJ (2007) p53 regulates maternal reproduction through LIF. Nature 450:721-724.
86. Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR (1995) High-frequency developmental abnormalities in p53-deficient mice. Curr Biol 5:931-936.
87. Sah VP, et al. (1995) A subset of p53-deficient embryos exhibit exencephaly. Nat Genet 10:175-180.
88. Cho Y, Gorina S, Jeffrey PD, Pavletich NP (1994) Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265:346-355. (Pubitemid 24259959)
89. Khoo KH, Joerger AC, Freund SM, Fersht AR (2009) Stabilising the DNA-binding domain of p53 by rational design of its hydrophobic core. Protein Eng Des Sel 22:421-430.
90. Suad O, et al. (2009) Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations. J Mol Biol 385:249-265.
91. Malecka KA, Ho WC, Marmorstein R (2009) Crystal structure of a p53 core tetramer bound to DNA. Oncogene 28:325-333.
92. Boeckler FM, et al. (2008) Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA 105:10360-10365.
93. Kwon E, Kim DY, Suh SW, Kim KK (2008) Crystal structure of the mouse p53 core domain in zinc-free state. Proteins 70:280-283.
94. Joerger AC, Ang HC, Fersht AR (2006) Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci USA 103: 15056-15061.
95. Ho WC, Fitzgerald MX, Marmorstein R (2006) Structure of the p53 core domain dimer bound to DNA. J Biol Chem 281:20494-20502. (Pubitemid 44065822)
96. Canadillas JM, et al. (2006) Solution structure of p53 core domain: Structural basis for its instability. Proc Natl Acad Sci USA 103:2109-2114.
97. Zhao K, Chai X, Johnston K, Clements A, Marmorstein R (2001) Crystal structure of the mouse p53 core DNA-binding domain at 2.7 A resolution. J Biol Chem 276: 12120-12127.
98. Kitayner M, et al. (2010) Diversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs. Nat Struct Mol Biol 17:423-429.
99. Huyen Y, et al. (2004) Structural differences in the DNA binding domains of human p53 and its C. elegans ortholog Cep-1. Structure 12:1237-1243. (Pubitemid 38900766)
100. Kim CA, Bowie JU (2003) SAM domains: Uniform structure, diversity of function. Trends Biochem Sci 28:625-628.
101. Rinne T, Brunner HG, van Bokhoven H (2007) p63- associated disorders. Cell Cycle 6:262-268.
102. Ou HD, Löhr F, Vogel V, Mäntele W, Dötsch V (2007) Structural evolution of C-terminal domains in the p53 family. EMBO J 26:3463-3473.
103. Chène P (2001) The role of tetramerization in p53 function. Oncogene 20:2611-2617.
104. Shaulian E, Zauberman A, Ginsberg D, Oren M (1992) Identification of a minimal transforming domain of p53: Negative dominance through abrogation of sequence-specific DNA binding. Mol Cell Biol 12: 5581-5592.
105. Stürzbecher HW, et al. (1992) A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization. Oncogene 7: 1513-1523.
106. Chan WM, Siu WY, Lau A, Poon RY (2004) How many mutant p53 molecules are needed to inactivate a tetramer? Mol Cell Biol 24:3536-3551.
107. Jeffrey PD, Gorina S, Pavletich NP (1995) Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 267: 1498-1502.
108. Lee W, et al. (1994) Solution structure of the tetrameric minimum transforming domain of p53. Nat Struct Biol 1:877-890.
109. Coutandin D, et al. (2009) Conformational stability and activity of p73 require a second helix in the tetramerization domain. Cell Death Differ 16: 1582-1589.
110. Joerger AC, et al. (2009) Structural evolution of p53, p63, and p73: Implication for heterotetramer formation. Proc Natl Acad Sci USA 106:17705-17710.
111. Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW (2006) p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 9:45-56.
112. Li Y, Prives C (2007) Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 26:2220-2225.
113. Hupp TR, Meek DW, Midgley CA, Lane DP (1992) Regulation of the specific DNA binding function of p53. Cell 71:875-886.
114. Hupp TR, Sparks A, Lane DP (1995) Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 83:237-245.
115. Halazonetis TD, Kandil AN (1993) Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J 12:5057-5064.
116. Prives C, Hall PA (1999) The p53 pathway. J Pathol 187:112-126.
117. Wang Y, et al. (1993) p53 domains: Identification and characterization of two autonomous DNA-binding regions. Genes Dev 7:2575-2586. (Pubitemid 24021014)
118. Anderson ME, Woelker B, Reed M, Wang P, Tegtmeyer P (1997) Reciprocal interference between the sequence-specific core and nonspecific C-terminal DNA binding domains of p53: Implications for regulation. Mol Cell Biol 17:6255-6264.
119. Lee S, Elenbaas B, Levine A, Griffith J (1995) p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 81:1013-1020.
120. Selivanova G, et al. (1996) The single-stranded DNA end binding site of p53 coincides with the C-terminal regulatory region. Nucleic Acids Res 24:3560-3567.
121. Reed M, et al. (1995) The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. Proc Natl Acad Sci USA 92:9455-9459.
122. Espinosa JM, Emerson BM (2001) Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol Cell 8:57-69.
123. Kim E, Albrechtsen N, Deppert W (1997) DNA-conformation is an important determinant of sequence-specific DNA binding by tumor suppressor p53. Oncogene 15:857-869. (Pubitemid 27390139)
124. Kim E, et al. (1999) Influence of promoter DNA topology on sequence-specific DNA binding and transactivation by tumor suppressor p53. Oncogene 18:7310-7318.
125. Jett SD, Cherny DI, Subramaniam V, Jovin TM (2000) Scanning force microscopy of the complexes of p53 core domain with supercoiled DNA. JMol Biol 299:585-592.
126. Nyman U, et al. (2009) Protein kinase C-dependent phosphorylation regulates the cell cycle-inhibitory function of the p73 carboxy terminus transactivation domain. Mol Cell Biol 29:1814-1825.
127. Rajagopalan S, Jaulent AM, Wells M, Veprintsev DB, Fersht AR (2008) 14-3-3 activation of DNA binding of p53 by enhancing its association into tetramers. Nucleic Acids Res 36:5983-5991.
128. Fernandez-Fernandez MR, Veprintsev DB, Fersht AR (2005) Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor. Proc Natl Acad Sci USA 102:4735-4740.
129. Wagner P, Fuchs A, Götz C, Nastainczyk W, Montenarh M (1998) Fine mapping and regulation of the association of p53 with p34cdc2. Oncogene 16:105-111. (Pubitemid 28043514)
130. Wagner P, Fuchs A, Prowald A, Montenarh M, Nastainczyk W (1995) Precise mapping of the tms1 binding site on p53. FEBS Lett 377:155-158.
131. Huang J, et al. (2007) p53 is regulated by the lysine demethylase LSD1. Nature 449:105-108.
132. Kachirskaia I, et al. (2008) Role for 53BP1 Tudor domain recognition of p53 dimethylated at lysine 382 in DNA damage signaling. J Biol Chem 283: 34660-34666.
133. Garnier J, Gibrat JF, Robson B (1996) GOR method for predicting protein secondary structure from amino acid sequence. Methods Enzymol 266:540-553. (Pubitemid 26165888)